• Organogenesis Holdings Inc ORGO.OQ ORGO.O is expected to show a rise in quarterly revenue when it reports results on November 12 for the period ending September 30 2024

• The Canton Massachusetts-based company is expected to report a 0.3% increase in revenue to $108.833 million from $108.53 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.The company's guidance on August 8 2024, for the period ended September 30, was for revenue between $105.00 million and $113.00 million.

• ​LSEG's mean analyst estimate for Organogenesis Holdings Inc is for a loss of 1 cent per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".​

• Wall Street's median 12-month price target for Organogenesis Holdings Inc is $4.25​, above​ its last closing price of $3.26. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

This summary was machine generated November 8 at 21:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)